Studies in primary mediastinal large B-cell lymphoma (PMBL) employing third-generation chemotherapy regimens.
| Reference . | Setting . | n . | Regimen . | RT . | IPI Low/High (%) . | CR/CR(u) . | PR . | Overall survival . | Progression- free survival . |
|---|---|---|---|---|---|---|---|---|---|
| * CR defined by normal mediastinal contour by CXR, with or without residual minor CT abnormalities | |||||||||
| ** For CR all masses had to have disappeared for 3 months. All other responses were PR | |||||||||
| † CR defined as complete regression of assessable disease of ≥ 80% response of residual mass | |||||||||
| ‡ Near CR is included, defined as ≥ 90% reduction in size of mass | |||||||||
| § CR(u) persistence of mass with having demonstrated ≥ 80% reduction | |||||||||
| Abbreviations: MACOP, methotrexate, leucovorin, adriamycin, cyclophosphamide, vincristine, prednisolone; MACOP-B, MACOP plus bleomycin; VACOP, etoposide, adriamycin, cyclophosphamide, vincristine, prednisolone; DA-EPOCH, dose-adjusted etoposide, vincristine, doxorubicin cyclophosphamide, prednisone; R, rituximab; ProMace, methotrexate, doxorubicin, cyclophosphamide, etoposide; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ProMace-CytaBOM, prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate, leucovorin; NHL-15, doxorubicin, vincristine, cyclophosphamide, granulocyte colony-stimulating factor. | |||||||||
| RT, radiotherapy; I-CT, induction chemotherapy; RFS, relapse-free survival; EFS, event-free sur vival; FU, follow-up; y, year; CR, complete remission; PR, partial remission | |||||||||
| Todeschini 1990 | Single center | 12 | MACOP-B (12 pts from series of 21) | Yes (67%) | — | 83% | 17% | — | — |
| Bertini 1991 | All stage II | 18 | MACOP-B | Yes (39%) | — | 16/27 | 1/18 | 77% at 3 y | 83% at 3 y |
| Lazzarino 1993 | Single center | 15 | MACOP-B/VACOP-B | Yes | — | 11/15* | 4/15 | — | — |
| Martelli 1998 | Single center (0 post I-CT) | 27 | MACOP-B | Yes | — | 3/27** | 23/27 | 93% at 2.2 y | 91% at 2 y |
| Zinznani 1999 | 2 centers | 50 | MACOP-B | Yes | — | 86% | — | 82% at 8 y | 93% at 3¼ y (RFS) |
| Zinzani 2001 | 8 centers | 89 | MACOP-B | Yes 26% post I-CT | — | 88%† | 4% | 86% at 9 y | 91% at 9 y (RFS) |
| Zinzani 2002 | IELSG mulitcenter retrospective | 277 | MACOP-B/VACOP-B ProMACE CytaBOM | Yes (51% post I-CT) | 82/18 | 79% | 9% | 71% at 10 y | 67% at 10 y |
| Todeschini 2004 | 13 centers | 138 | MACOP/VACOP-B | Yes | 67/33 | 80%‡ | 10% | — | 76% at 5 y (EFS) |
| Hamblin 2005 | Single institution | 68 | NHL-15 | No | 75/25 | 88% | 3% | 84% at median FU 10.9 y | 60% at median FU 10.9 y (EFS) |
| Savage 2006 | Population based | 47 | MACOP-B/VACOP-B | Dependent upon era | — | — | — | 87% at 5 y | — |
| Dunleavy 2006 | Single institution | 44 | DA-EPOCH (n = 18) R + DA-EPOCH (n = 26) | No | — | — | — | 78% at 9.5 y FU 100% at 4.2 y FU | 67% at 9.5 y (EFS) 91% at 4.2 y (EFS) |
| Mazzarotto 2007 | Single institution | 53 | ProMACE-MOPP/MACOP-B/VACOP-B | Yes (81%) | 87/13 | 86% 38% post I-CT | — | 87% at 5 y | 93% at 5 y |
| De Sanctis 2008 | Single institution | 92 | MACOP-B | Yes | 57/43 | 87%§ | 9% | 87% at 5 y | 81% at 5 y |
| Reference . | Setting . | n . | Regimen . | RT . | IPI Low/High (%) . | CR/CR(u) . | PR . | Overall survival . | Progression- free survival . |
|---|---|---|---|---|---|---|---|---|---|
| * CR defined by normal mediastinal contour by CXR, with or without residual minor CT abnormalities | |||||||||
| ** For CR all masses had to have disappeared for 3 months. All other responses were PR | |||||||||
| † CR defined as complete regression of assessable disease of ≥ 80% response of residual mass | |||||||||
| ‡ Near CR is included, defined as ≥ 90% reduction in size of mass | |||||||||
| § CR(u) persistence of mass with having demonstrated ≥ 80% reduction | |||||||||
| Abbreviations: MACOP, methotrexate, leucovorin, adriamycin, cyclophosphamide, vincristine, prednisolone; MACOP-B, MACOP plus bleomycin; VACOP, etoposide, adriamycin, cyclophosphamide, vincristine, prednisolone; DA-EPOCH, dose-adjusted etoposide, vincristine, doxorubicin cyclophosphamide, prednisone; R, rituximab; ProMace, methotrexate, doxorubicin, cyclophosphamide, etoposide; MOPP, mechlorethamine, vincristine, procarbazine, prednisone; ProMace-CytaBOM, prednisone, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate, leucovorin; NHL-15, doxorubicin, vincristine, cyclophosphamide, granulocyte colony-stimulating factor. | |||||||||
| RT, radiotherapy; I-CT, induction chemotherapy; RFS, relapse-free survival; EFS, event-free sur vival; FU, follow-up; y, year; CR, complete remission; PR, partial remission | |||||||||
| Todeschini 1990 | Single center | 12 | MACOP-B (12 pts from series of 21) | Yes (67%) | — | 83% | 17% | — | — |
| Bertini 1991 | All stage II | 18 | MACOP-B | Yes (39%) | — | 16/27 | 1/18 | 77% at 3 y | 83% at 3 y |
| Lazzarino 1993 | Single center | 15 | MACOP-B/VACOP-B | Yes | — | 11/15* | 4/15 | — | — |
| Martelli 1998 | Single center (0 post I-CT) | 27 | MACOP-B | Yes | — | 3/27** | 23/27 | 93% at 2.2 y | 91% at 2 y |
| Zinznani 1999 | 2 centers | 50 | MACOP-B | Yes | — | 86% | — | 82% at 8 y | 93% at 3¼ y (RFS) |
| Zinzani 2001 | 8 centers | 89 | MACOP-B | Yes 26% post I-CT | — | 88%† | 4% | 86% at 9 y | 91% at 9 y (RFS) |
| Zinzani 2002 | IELSG mulitcenter retrospective | 277 | MACOP-B/VACOP-B ProMACE CytaBOM | Yes (51% post I-CT) | 82/18 | 79% | 9% | 71% at 10 y | 67% at 10 y |
| Todeschini 2004 | 13 centers | 138 | MACOP/VACOP-B | Yes | 67/33 | 80%‡ | 10% | — | 76% at 5 y (EFS) |
| Hamblin 2005 | Single institution | 68 | NHL-15 | No | 75/25 | 88% | 3% | 84% at median FU 10.9 y | 60% at median FU 10.9 y (EFS) |
| Savage 2006 | Population based | 47 | MACOP-B/VACOP-B | Dependent upon era | — | — | — | 87% at 5 y | — |
| Dunleavy 2006 | Single institution | 44 | DA-EPOCH (n = 18) R + DA-EPOCH (n = 26) | No | — | — | — | 78% at 9.5 y FU 100% at 4.2 y FU | 67% at 9.5 y (EFS) 91% at 4.2 y (EFS) |
| Mazzarotto 2007 | Single institution | 53 | ProMACE-MOPP/MACOP-B/VACOP-B | Yes (81%) | 87/13 | 86% 38% post I-CT | — | 87% at 5 y | 93% at 5 y |
| De Sanctis 2008 | Single institution | 92 | MACOP-B | Yes | 57/43 | 87%§ | 9% | 87% at 5 y | 81% at 5 y |